GlassScriptPhysician profile
Daniel Alberto Vaena
NPI 1578548376
$103,922.97
in general payments reported to CMS, 2019-2025
33 companies · $15K in 2025
The $15K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $10K · 2021: $28K · 2022: $23K · 2023: $9,045 · 2024: $18K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Travel and Lodging: $5,362 · Honoraria: $2,310 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,632 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,041.00 |
| Travel and Lodging | $5,361.70 |
| Honoraria | $2,310.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,631.85 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22,639.82 | 2019-2024 | Keytruda, Lenvima |
| Exelixis INC. | $10,815.82 | 2020-2024 | Cabometyx |
| Eisai INC. | $10,222.87 | 2021-2022 | |
| Emd Serono, INC. | $9,987.77 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $9,058.13 | 2024-2025 | Imfinzi, Truqap |
| E.R. Squibb & Sons, L.L.C. | $7,975.00 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $7,363.00 | 2020-2024 | |
| Seagen INC. | $6,149.15 | 2020-2023 | Padcev |
| Genzyme Corporation | $4,260.77 | 2022 | |
| Avyxa Pharma, LLC | $4,102.63 | 2025 | |
| Aveo Pharmaceuticals, INC. | $2,100.00 | 2021 | |
| Immunomedics, INC. | $2,025.00 | 2020 | |
| Astellas Pharma Global Development | $1,901.57 | 2024 | Padcev |
| Gilead Sciences, INC. | $1,741.53 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $1,127.91 | 2025 | Erleada, Carvykti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $900.00 | 2025 | Padcev |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Merck Kgaa | $255.00 | 2022 | |
| Pfizer INC. | $165.27 | 2021-2024 | |
| Celgene Corporation | $94.79 | 2024-2025 | Reblozyl |
| Tesaro, INC. | $76.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $66.74 | 2019 | |
| Caris Mpi, INC. | $44.76 | 2025 | Mi Cancer Seek |
| Coherus Oncology, INC. | $22.95 | 2023 | |
| Glaxosmithkline, LLC. | $20.13 | 2023 | Jemperli, Zejula |
| Amgen INC. | $17.98 | 2021 | |
| Taiho Oncology, INC. | $17.42 | 2024 | |
| Daiichi Sankyo INC. | $13.11 | 2023 | Injectafer |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vaena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.